TY - JOUR
T1 - A reassessment of risks and benefits of dopamine agonists in Parkinson's disease
AU - Antonini, Angelo
AU - Tolosa, Eduardo
AU - Mizuno, Yoshikuni
AU - Yamamoto, Mitsutoshi
AU - Poewe, Werner H.
PY - 2009/10
Y1 - 2009/10
N2 - Neurologists have several choices of drugs that have been shown to be effective for the treatment of the symptoms of Parkinson's disease. Among the first options are the dopamine agonists, which are commonly used both as an early monotherapy and as an adjunct therapy to levodopa. However, before starting any treatment, the overall benefit-to-risk ratio to individual patients must be considered. For the dopamine agonists, the available evidence on their symptomatic efficacy, effect on long-term levodopa-related motor complications, putative effect on progression of disease, and adverse event profile must be taken into account. Recently, the ocurrence of adverse events such as leg oedema, daytime somnolence, impulse control disorders, and fibrosis have increasingly been recognised. The risks of these potentially serious adverse events must therefore be taken into account and treatment decisions should be based on considerations of risks versus benefits for individual patients.
AB - Neurologists have several choices of drugs that have been shown to be effective for the treatment of the symptoms of Parkinson's disease. Among the first options are the dopamine agonists, which are commonly used both as an early monotherapy and as an adjunct therapy to levodopa. However, before starting any treatment, the overall benefit-to-risk ratio to individual patients must be considered. For the dopamine agonists, the available evidence on their symptomatic efficacy, effect on long-term levodopa-related motor complications, putative effect on progression of disease, and adverse event profile must be taken into account. Recently, the ocurrence of adverse events such as leg oedema, daytime somnolence, impulse control disorders, and fibrosis have increasingly been recognised. The risks of these potentially serious adverse events must therefore be taken into account and treatment decisions should be based on considerations of risks versus benefits for individual patients.
UR - http://www.scopus.com/inward/record.url?scp=69949085340&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=69949085340&partnerID=8YFLogxK
U2 - 10.1016/S1474-4422(09)70225-X
DO - 10.1016/S1474-4422(09)70225-X
M3 - Article
C2 - 19709931
AN - SCOPUS:69949085340
VL - 8
SP - 929
EP - 937
JO - The Lancet Neurology
JF - The Lancet Neurology
SN - 1474-4422
IS - 10
ER -